Clinical DevelopmentsCarisma's lead therapeutic has shown promise for solid tumors, with initial clinical data suggesting that the CT-0508/pembro combination is encouraging for this challenging indication.
Potential PartnershipsCompelling data from Carisma's upcoming presentations could attract significant partnerships, potentially accelerating the development of their innovative fibrosis program.
Preclinical AdvancementsPreclinical models indicate that Carisma's engineered macrophages can reverse liver and lung fibrosis, offering hope for new treatments in diseases with limited options.